2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes
|
|
|
- Leslie Stone
- 5 years ago
- Views:
Transcription
1 Malignant lymphoma, NOS 9590/3 Non-Hodgkin lymphoma, NOS 9591/3 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma 9596/3 Primary cutaneous follicle centre lymphoma 9597/3 Classical Hodgkin lymphoma 9650/3 Lymphocyte-rich classical Hodgkin lymphoma 9651/3 Mixed cellularity classical Hodgkin lymphoma 9652/3 Lymphocyte-depleted classical Hodgkin lymphoma 9653/3 Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis [OBS] 9654/3 Hodgkin lymphoma, lymphocyte depletion, reticular 9655/3 Hodgkin disease, lymphocytic predominance, NOS [OBS] See 9651/3 9657/3 Hodgkin disease, lymphocytic predominance, diffuse [OBS] See 9651/3 9658/3 Nodular lymphocyte predominant Hodgkin lymphoma 9659/3 Hodgkin granuloma [OBS] 9661/3 Hodgkin sarcoma [OBS] 9662/3 Nodular sclerosis classical Hodgkin lymphoma 9663/3 Hodgkin lymphoma, nodular sclerosis, cellular phase [OBS] See 9663/3 9664/3 Hodgkin lymphoma, nodular sclerosis, grade 1 [OBS] See 9663/3 9665/3 Hodgkin lymphoma, nodular sclerosis, grade 2 [OBS] See 9663/3 9667/3 Malignant lymphoma, small B lymphocytic, NOS [OBS] See 9823/3 9670/3 Lymphoplasmacytic lymphoma 9671/3 Mantle cell lymphoma 9673/3 Malignant lymphoma, mixed small and large cell, diffuse [OBS] See 9690/3 9675/3 Primary effusion lymphoma 9678/3 Primary mediastinal (thymic) large B-cell lymphoma 9679/3 Diffuse large B-cell lymphoma (DLBCL) 9680/3 Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS [OBS] See 9680/3 9684/3 Burkitt lymphoma 9687/3 T-cell/histiocyte rich large B-cell lymphoma 9688/3 Splenic marginal zone lymphoma 9689/3 Follicular lymphoma 9690/3 Follicular lymphoma, grade /3
2 Follicular lymphoma, grade /3 Follicular lymphoma, grade /3 Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) 9699/3 Mycosis fungoides 9700/3 Sezary syndrome 9701/3 Peripheral T-cell lymphoma, NOS 9702/3 Angioimmunoblastic T-cell lymphoma 9705/3 Subcutaneous panniculitis-like T-cell lymphoma 9708/3 Primary cutaneous T-cell lymphoma 9709/3 Intravascular large B-cell lymphoma 9712/3 Anaplastic large cell lymphoma, ALK positive 9714/3 Hepatosplenic T-cell lymphoma 9716/3 Enteropathy-associated T-cell lymphoma 9717/3 Primary cutaneous CD30-positive T-cell lymphoproliferative disorders 9718/3 Extranodal NK/T cell lymphoma, nasal type 9719/3 Systemic EBV positive T-cell lymphoproliferative disease of childhood 9724/3 Hydroa vacciniforme-like lymphoma 9725/3 Primary cutaneous gamma-delta T-cell lymphoma 9726/3 Blastic plasmacytoid dendritic cell neoplasm 9727/3 Precursor B-cell lymphoblastic lymphoma [OBS] See 9811/3 9728/3 Precursor T-cell lymphoblastic lymphoma [OBS] See 9837/3 9729/3 Solitary plasmacytoma of bone 9731/3 Plasma cell myeloma 9732/3 Plasma cell leukemia [OBS] See 9732/3 9733/3 Extraosseous plasmacytoma 9734/3 Plasmablastic lymphoma 9735/3 ALK positive large B-cell lymphoma 9737/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease 9738/3 Mast cell sarcoma 9740/3 Systemic mastocytosis 9741/3 Mast cell leukemia 9742/3 Malignant histiocytosis [OBS] See 9751/3 9750/3
3 Langerhans cell histiocytos 9751/3 Langerhans cell histiocytosis, unifocal [OBS] See 9751/3 9752/3 Langerhans cell histiocytosis, multifocal [OBS] See 9751/3 9753/3 Langerhans cell histiocytosis, disseminated [OBS] See 9751/3 9754/3 Histiocytic sarcoma 9755/3 Langerhans cell sarcoma 9756/3 Interdigitating dendritic cell sarcoma 9757/3 Follicular dendritic cell sarcoma 9758/3 Fibroblastic reticular cell tumor 9759/3 Immunoproliferative disease, NOS [OBS] 9760/3 Waldenstrom macroglobulinemia 9761/3 Heavy chain disease 9762/3 Immunoproliferative small intestinal disease [OBS] See 9762/3 9764/3 Monoclonal gammopathy, unknown signifance (MGUS) 9765/1 Leukemia, NOS 9800/3 Acute undifferentiated leukemia 9801/3 Acute biphenotypic leukemia [OBS] 9805/3 Mixed phenotype acute leukemia with t(9;22(q34;q11.2);bcr-abl1 9806/3 Mixed phenotype acute leukemia with t(v;11q23);mll, rearranged 9807/3 Mixed phenotype acute leukemia, B/myeloid, NOS 9808/3 Mixed phenotype acute leukemia, T/myeloid, NOS 9809/3 B lymphoblastic leukemia/lymphoma, NOS 9811/3 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2);bcr-abl1 9812/3 B lymphoblastic leukemia/lymphoma with t(v;11q23);mll rearranged 9813/3 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22);tel-aml1 (ETV6-RUNX1) 9814/3 B lymphoblastic leukemia/lymphoma with hyperdiploidy 9815/3 B lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL) 9816/3 B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32);il3-igh 9817/3 B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);e2a-pbx1 (TCF3-PBX1) 9818/3 Lymphoid leukemia, NOS 9820/3 Chronic lymphocytic leukemia/small lymphocytic lymphoma 9823/3 Burkitt cell leukemia 9826/3
4 Adult T-cell leukemia/lymphoma (HTLV-1 positive) 9827/3 T-cell large granular lymphocytic leukemia 9831/3 Prolymphocytic leukemia, NOS 9832/3 B-cell prolymphocytic leukemia 9833/3 T-cell prolymphocytic leukemia 9834/3 Precursor cell lymphoblastic leukemia, NOS [OBS] See 9811/3 9835/3 Precursor B-cell lymphoblastic leukemia [OBS] See 9811/3 9836/3 Adult T-cell leukemia/lymphoma 9837/3 Acute erythroid leukemia 9840/3 Myeloid leukemia, NOS 9860/3 Acute myeloid leukemia, NOS 9861/3 Chronic myeloid leukemia, NOS 9863/3 Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUP /3 Acute promyelocytic leukemia (AML with t(15;17)(q22;q12), PML/RARA 9866/3 Acute myelomonocytic leukemia 9867/3 Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3;3)(q21;q26;2); RPN1-EVI1 9869/3 Acute basophilic leukemia 9870/3 Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22), CBFB/MYH /3 Acute myeloid leukemia with minimal differentiation 9872/3 Acute myeloid leukemia without maturation 9873/3 Acute myeloid leukemia with maturation 9874/3 Chronic myelogenous leukemia, BCR-ABL1 positive 9875/3 Atypical chronic myeloid leukemia, BCR-ABL1 negative 9876/3 Acute monoblastic and monocytic leukemia 9891/3 Acute myeloid leukemia with myelodysplasia-related changes 9895/3 Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1 9896/3 Acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL 9897/3 Myeloid leukemia associated with Down syndrome 9898/3 Acute megakaryoblastic leukemia 9910/3 Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13);rbm15-mkl1 9911/3 Therapy-related myeloid neoplasm 9920/3 Myeloid sarcoma 9930/3
5 Acute panmyelosis with myelofibrosis 9931/3 Hairy cell leukemia 9940/3 Chronic myelomonocytic leukemia 9945/3 Juvenile myelomonocytic leukemia 9946/3 Aggressive NK-cell leukemia 9948/3 Polycythemia vera 9950/3 Chronic myeloproliferative disease, NOS [OBS] See 9975/3 9960/3 Primary myelofibrosis 9961/3 Essential thrombocythemia 9962/3 Chronic neutrophilic leukemia 9963/3 Chronic eosinophilic leukemia, NOS 9964/3 Myeloid and lymphoid neoplasm with PDGFRA rearrangement 9965/3 Myeloid neoplasm with PDGFRB arrangement 9966/3 Myeloid and lymphoid neoplasm with FGFR1 abnormalities 9967/3 Lymphoproliferative disorder, NOS 9970/1 Post Transplant Lymphoproliferative Disorder (PTLD) 9971/3 Myelodysplastic/myeloproliferative neoplasm, unclassifiable 9975/3 Refractory anemia 9980/3 Refractory anemia with ring sideroblasts 9982/3 Refractory anemia with excess blasts 9983/3 Refractory anemia with excess blasts in transformation [OBS] See 9983/3 9984/3 Refractory cytopenia with multilineage dysplasia 9985/3 Myelodyasplastic syndrome associated with isolated del(5q) 9986/3 Therapy related myelodysplastic syndrome, NOS [OBS] See 9920/3 9987/3 Myelodysplasic syndrome, unclassifiable 9989/3 Refractory neutropenia 9991/3 Refractory thrombocytopenia 9992/3
2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Acute basophilic leukemia 9870/3 Acute biphenotypic leukemia [OBS] 9805/3 Acute erythroid leukemia 9840/3 Acute megakaryoblastic leukemia 9910/3 Acute monoblastic and monocytic leukemia 9891/3 Acute myeloid
Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation
Major subgroups according to the World Health Organisation (WHO) Classification Myeloproliferative neoplasms (MPN) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or
Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
Introduction: The Revised (4 th Edition) World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues
Society for Hematopathology Scientific Symposium USCAP Companion Meeting, Boston, MA March 8, 2009 Boston, MA Steven H. Swerdlow and James Vardiman, Moderators Introduction: The Revised (4 th Edition)
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual KCR 2018 SPRING TRAINING 2018 Hematopoietic Database Updates Updates were done to the Hematopoietic Database based on the WHO Hematopoietic
Myeloid malignancies Chronic myeloid disorders
Myeloid malignancies Chronic myeloid disorders Myeloproliferative neoplasms (MPN) Mastocytosis / Mast cell diseases Myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement Myelodysplastic/myeloproliferative
Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow*
Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow* Version: Protocol Posting Date: January 2018 This protocol is NOT required for accreditation
Reviewing the ICD-10 classification of haematological neoplasms on its way to ICD-11
WHO-FIC NETWORK MEETING Tokyo, Japan haematological neoplasms on its way to ICD-11 Ulrich Vogel, Robert Jakob, Michael Schopen, Harald Stein, Stefan Krause Abstract: haematological neoplasms on its way
Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
Hepatic Lymphoma Diagnosis An Algorithmic Approach
Hepatic Lymphoma Diagnosis An Algorithmic Approach Ryan M. Gill, M.D., Ph.D. University of California, San Francisco PLEASE TURN OFF YOUR CELL PHONES Disclosure of Relevant Financial Relationships USCAP
Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307
Clinical Policy: (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that
The College of American Pathologists offers these protocols
Strategies for Laboratory and Patient Management Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms of the Bone Marrow A Basis for Checklists LoAnn C. Peterson, MD; Steven
Contractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC A. LCD ID Number: L35032 Status: A-Approved
LCD for Flow Cytometry (L35032) Contractor Name: Novitas Solutions, Inc. Contractor Number: 12501 Contractor Type: MAC A LCD ID Number: L35032 Status: A-Approved Contractor Information LCD Information
Classifications of lymphomas
Classifications of lymphomas Lukes and Collins Kiel classification Working formulation REAL classification (1994) WHO classification (2000) WHO CLASSIFICATIONF OF NEOPLASMS HAEMATOPETIC AND LYMPHOID TISSUES
Integrated Hematopathology. Morphology and FCI with IHC
Integrated Hematopathology Morphology and FCI with IHC FrontMatter.indd i 9/6/2009 9:30:12 PM FrontMatter.indd ii 9/6/2009 9:30:18 PM Integrated Hematopathology Morphology and FCI with IHC Cherie H Dunphy,
WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia
Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra WHO classification
COPYRIGHTED MATERIAL. Introduction CHAPTER 1. Examination of p atients. Classification of c utaneous l ymphomas. Staging i nvestigations
CHAPTER 1 Introduction Primary cutaneous lymphomas represent distinct clinical and histopathologic subtypes of extranodal lymphomas. They can be defined as neoplasms of the immune system, characterized
Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow
Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow Based on AJCC/UICC TNM, 7 th Edition Protocol web posting date: February 1, 2011 Procedures
Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.
Non-Hodgkin Lymphoma Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract. Protocol revision date: January 2005 No AJCC/UICC staging system Procedures Cytology
Hematology Page 1 of 8
Hematology Page 1 of 8 Hematology Major Category Code Headings Revised 12/17 1 Basic methodology and test armamentarium 20000 2 Normal hematopoiesis & hemostasis 20100 3 RBC disorders, non-neoplastic 20340
The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:
Hematology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified hematologist
Contents. vii. Preface... Acknowledgments... v xiii
Contents Preface... Acknowledgments... v xiii SECTION I 1. Introduction... 3 Knowledge-Based Diagnosis... 4 Systematic Examination of the Lymph Node... 7 Cell Type Identification... 9 Cell Size and Cellularity...
Practical Diagnosis of Hematologic Disorders. Vol 2 Malignant Disorders
5 th ed Practical Diagnosis of Hematologic Disorders Vol 2 Malignant Disorders Vol2_FrontMatter_v03_0804 final.indd i 8/6/2009 10:00:11 PM Authors Carl R Kjeldsberg, MD Professor of Pathology, University
Classification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
WHO Classification 7/2/2009
Least Malignant Myeloproliferative Disorders Myelodysplastic Syndromes Most Malignant Acute Leukemia Classifying Hematopoietic Disorders French-American-British (FAB) World Health Organization (WHO) Thanks
THE SOCIETY FOR Hematopathology and the European
SPECIAL ARTICLE World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting Airlie House, Virginia, November
WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities
WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities Robert W. McKenna, M.D. 1/2009 WHO Classification of Myeloid Neoplasms (4th Edition)--2008 Incorporates new information that
Protocol for the Examination of Hematologic Malignancies in Bone Marrow
Protocol for the Examination of Hematologic Malignancies in Bone Marrow Version: Bone Marrow 4.0.0.0 Protocol Posting Date: February 2019 Accreditation Requirements The use of this protocol is recommended
癌症診療準則與核心測量 - 淋巴瘤 彰化基督教醫院內科部血液腫瘤科張正雄. Agenda
癌症診療準則與核心測量 - 淋巴瘤 彰化基督教醫院內科部血液腫瘤科張正雄 Agenda Lymphocyte differentiation Classification of lymphomas Disease definitions and symptoms Tests that identify specific lymphoid histologies Staging Cancer registry
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual KCR 2018 SPRING TRAINING 2018 Hematopoietic Database Updates Updates were done to the Hematopoietic Database based on the WHO Hematopoietic
Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307
Clinical Policy: (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: 02/17 Last Review Date: 02/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
During past decades, because of the lack of knowledge
Staging and Classification of Lymphoma Ping Lu, MD In 2004, new cases of non-hodgkin s in the United States were estimated at 54,370, representing 4% of all cancers and resulting 4% of all cancer deaths,
HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint
HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Hematology MOC exam blueprint Based on feedback from physicians that MOC assessments should
Small B-cell (Histologically Low Grade) Lymphoma
Frequency of Lymphoid Neoplasms Small B-cell (Histologically Low Grade) Lymphoma Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital B-cell neoplasms 88% Diffuse large B-cell lymphoma
HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor
HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor I. Description of the rotation: During this rotation, the resident will gain
HEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS)
Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS) Operational Policy Version 4-26.09.12 Operational Policy for the Oxford NHS/BRC SIHMDS 1. Introduction...4 1.1 Objectives...4
Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
B980 B968. C836 Diffuse non-hodgkin's lymphoma, undifferentiated (diffuse) C839 Non-follicular diffuse non-hodgkin lymphoma, unspecified
รหะส ICD ท ยกเล ก (ตาม DRG 5.1.1) รหะสท ยกเล ก Description รหะสท ใช Description A090 Other and unspecified gastroenteritis and colitis of infectious origin A09 Diarrhoea and gastroenteritis of presumed
Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms
Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms Version: Protocol Posting Date: October 2013 This protocol is NOT required for accreditation purposes
Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University
Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic
Non-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Use of Immunophenotyping/ Genetic Testing in Differential Diagnosis of Mature B-Cell
HEMATOPATHOLOGY. 2017/2018 2nd semester
HEMATOPATHOLOGY 2017/2018 2nd semester NORMAL HAEMOPOESIS COMMON MYELOID PRGENITOR HEMATOPOIETIC STEM CELL COMMON LYMPHOID PROGENITOR NK T B MEGAKARYO- BLAST PRONORMO- BLAST MONOBLAST MYELOBLAST PRO NK
Corrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run
Corrigenda WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run In addition to corrections of minor typographical errors, corrections
Hematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
Change Summary - Form 2018 (R3) 1 of 12
Summary - Form 2018 (R3) 1 of 12 Form Question Number (r3) Type Description New Text Previous Text Today's date was removed 2018 N/A Today's Date Removed from Key Fields 2018 N/A HCT Type 2018 N/A Product
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes Lauren R. Teras, PhD 1 ; Carol E. DeSantis, MPH 2 ; James R. Cerhan, MD, PhD 3 ; Lindsay M. Morton, PhD 4 ; Ahmedin Jemal, DVM,
Burkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8
Heme 8 Burkitt lymphoma Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8 Most common is t(8;14) Believed to be the fastest growing tumor in humans!!!! Morphology
Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
SAUDI FELLOWSHIP TRAINING PROGRAM. Adult Haematology. Final Written Examination 2019
SAUDI FELLOWSHIP TRAINING PROGRAM Adult Haematology Final Written Examination 2019 Examination Format: A. The Saudi fellowship specialty final written examination shall consist of one paper with 80-120
155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary
ICD-9 TO ICD-10 Reference ICD-9 150.9 Malignant neoplasm of esophagus unspecified site C15.9 Malignant neoplasm of esophagus, unspecified 151.9 Malignant neoplasm of stomach unspecified site C16.9 Malignant
MOC HEM - General Hematopathology (Mandatory 50-Question Module)
MOC HEM - General Hematopathology (Mandatory 50-Question Module) acute monoblastic/monocytic leukemia infectious mononucleosis adult T cell leukemia/lymphoma in situ follicular lymphoma ALL; phenotypes
Kylie Lepic BSc, MD, FRCPC CAGPO Conference
Acute Leukemia Kylie Lepic BSc, MD, FRCPC CAGPO Conference Oct 19, 2013 1 Disclosures No conflicts of interest 2 Objectives Case presentation Classification of leukemia Clinical manifestations Diagnosis
MOC HEM - General Hematopathology (Mandatory 50-Question Module)
MOC HEM - General Hematopathology (Mandatory 50-Question Module) acute monoblastic/monocytic leukemia infectious mononucleosis adult T cell leukemia/lymphoma in situ follicular lymphoma ALL; phenotypes
4000: Cellular Therapy Essential Data Pre-Infusion Form
4000: Cellular Therapy Essential Data Pre-Infusion Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: / / CIBMTR Form 4000 revision 3 (page 1 of 19). Last
GENETICS OF HEMATOLOGICAL MALIGNANCIES
de DUVE INSTITUTE GENETICS OF HEMATOLOGICAL MALIGNANCIES INTERUNIVERSITY CERTIFICATE IN HUMAN GENETICS Université catholique de Louvain Brussels,19/02/2016 Professor Hélène Antoine-Poirel, MD, PhD Center
3.1 Introduction. It is emphasised that not all tests are necessarily required in every case. 3.2 Taxonomic structure
CHAPTER 3 CLASSIFICATION 3.1 Introduction Accurate diagnosis underpins lymphoma management. Historically, competing lymphoma classifications have been a source of frustration to pathologists, clinicians
Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms
Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms Protocol applies to non-hodgkin lymphoma/lymphoid neoplasms involving any site except the ocular adnexa,
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
Hematopoietic Neoplasms Best Coding Practices Edition
Hematopoietic Neoplasms Best Coding Practices 2015-16 Edition Presentation developed by April Fritz, RHIT, CTR Hematopoietic Neoplasms Coding Best Practices 1 Heme and Lymph Coding Rules Still causing
5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
DETERMINATION OF A LYMPHOID PROCESS
Chapter 2 Applications of Touch Preparation Cytology to Intraoperative Consultations: Lymph Nodes and Extranodal Tissues for Evaluation of Hematolymphoid Disorders INTRODUCTION As discussed in Chap. 1,
Saudi Fellowship Training Program. Final Written Examination of Adult Hematology 2018
Saudi Fellowship Training Program Final Written Examination of Adult Hematology 2018 Objectives: Determine the quantity and quality of a hematologist s knowledge base ranked as competent, so that the individual
Plasma cell myeloma (multiple myeloma)
Plasma cell myeloma (multiple myeloma) Common lymphoid neoplasm, present at old age (70 years average) Remember: plasma cells are terminally differentiated B-lymphocytes that produces antibodies. B-cells
Pathology of Hematopoietic and Lymphoid tissue
Pathology of Hematopoietic and Lymphoid tissue Peerayut Sitthichaiyakul, M.D. Department of Pathology and Forensic Medicine Faculty of Medicine, Naresuan University CONTENTS White blood cells and lymph
Commentary. N. L. Harris, 1 E. S. Jaffe, 2 J. Diebold, 3 G. Flandrin, 4 H. K. Muller-Hermelink, 5 J.Vardiman, 6 T. A. Lister 7 & C. D.
Annals of Oncology 10: 1419-1432. 1999. 1999 Khmer Academic Publishers Printedm the Netherlands Commentary The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid
Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
MANAGEMENT OF LYMPHOMAS
MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association
Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham
Lymphoid Neoplasms Sylvie Freeman Department of Clinical Immunology, University of Birmingham Incidence of Haematological Malignancies UK2001 (CRUK) Malignancy New Cases All Cancers 271,000 Leukaemia 6,760
Update on the WHO Classification of Acute Myeloid Leukemia. Kaaren K. Reichard, MD Mayo Clinic Rochester
Update on the WHO Classification of Acute Myeloid Leukemia Kaaren K. Reichard, MD Mayo Clinic Rochester reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Objectives Present a practical
88-year-old Female with Lymphadenopathy. Faizi Ali, MD
88-year-old Female with Lymphadenopathy Faizi Ali, MD Clinical History A 88-year-old caucasian female presented to our hospital with the complaints of nausea, vomiting,diarrhea, shortness of breath and
Sub-Class Code Sub-Classification Other code Other classification. Bone Marrow failures including 7 Aplastic Anaemia 77 Other 1 Acquired
ification ification Other code Other classification Absence of T & B cells SCID 8 Inherited Disorders 1 Primary immune deficiencies Absence of T, normal B cell SCID 8 Inherited Disorders 1 Primary immune
The spectrum of flow cytometry of the bone marrow
The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests
Pathology of Hematopoietic and Lymphoid tissue
CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis
Sub-Class Code Sub-Classification Other code Other classification. Bone Marrow failures including 7 Aplastic Anaemia 77 Other 1 Acquired
ification Sub- Sub-ification Other code Other classification Absence of T & B cells SCID 8 Inherited Disorders 1 Primary immune deficiencies Absence of T, normal B cell SCID 8 Inherited Disorders 1 Primary
AML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen
AML: WHO classification, biology and prognosis Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Acute myeloid leukemia Clonal expansion of undifferentiated myeloid precursors Impaired
Common Problem Areas. WHO Classification. Defines separate diseases (entities) with their CLINICAL AGGRESSIVENESS LOW GRADE / HIGH GRADE
WHO Classification Defines separate diseases (entities) with their CLINICAL AGGRESSIVENESS REVIEW OF MOST COMMON LYMPHOMA ENTITIES Dr Stefan Dojcinov LOW GRADE / HIGH GRADE (June 2014) The Non-Hodgkin
Immunopathology of Lymphoma
Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
Sub-Class Code Sub-Classification Other code Other classification. Bone Marrow failures including 7 Aplastic Anaemia 77 Other 1 Acquired
ification Sub- Sub-ification Other code Other classification Absence of T & B cells SCID 8 Inherited Disorders 1 Primary immune deficiencies Absence of T, normal B cell SCID 8 Inherited Disorders 1 Primary
12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization
Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,
3/5/2013. Hematopoiesis: Red and white marrow. Hematopoiesis. Bone marrow aspirate and core biopsy. Gartner, Color Textbook of Histology, 3 rd Edition
Hematopoiesis Hematopoiesis: Red and white marrow Bone marrow aspirate and core biopsy Gartner, Color Textbook of Histology, 3 rd Edition 1 reticulocytes elliptocytes schistocytes spheroctyes target cells
Many of the hematolymphoid disorders are derived
REVIEW ARTICLE Practical Immunohistochemistry in Hematopathology: A Review of Useful Antibodies for Diagnosis Ji Lu, MD and Karen L. Chang, MD Abstract: This review article offers some useful panels of
Aggressive B-cell Lymphoma 2013
Aggressive B-cell Lymphoma 2013 Diffuse Large B-Cell Lymphoma Burkitt Lymphoblastic lymphoma Gray zone Intermediate DLBCL/HL Intermediate BL/DLBCL Diffuse Large B-cell lymphoma Common morphology: diffuse
Case year old male with abdominal lymphadenopathy Treated with 8 cycles of R-CHOP One year later B-symptoms and progressive disease
Codirectors Tsieh Sun, M.D., FASCP Francisco Vega, M.D., Ph.D. Department of Hematopathology UT MD Anderson Cancer Center Houston Texas There is no conflict of interest involved in the content and presentation
7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
Recommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
2 nd step do Bone Marrow Study If possible both the aspiration and
Blood Malignancies-I Prof. Herman Hariman,SpPK a (KH). Ph.D.(U.K) Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. Clinpath, FK-USU First do the Full Blood Count Hb, WBCS, Platelets Morphology!! Such as blasts,
LYMPHOMAS an overview of some subtypes of NHLs
One of the confusing aspects of the lymphoid neoplasms concerns the use of the descriptive terms "leukemia" and "lymphoma." LYMPHOMAS an overview of some subtypes of NHLs Leukemia is used for lymphoid
A.C. Feller. J. Diebold Histopathology of Nodal and Extranodal Non-Hodgkin's Lymphomas
A.C. Feller. J. Diebold Histopathology of Nodal and Extranodal Non-Hodgkin's Lymphomas Springer Berlin Heidelberg New York Hong Kong London Milan Paris Tokyo Alfred C. Feller Jacques Diebold in Collaboration
HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING. Use of IHC. Use of Polymerase Chain Reaction (PCR) Use of Flow Cytometry
HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING The 2008 WHO classification system for tumors of hematopoietic and lymphoid tissues specifies that various combinations of immunophenotypic
5000 International Clinical Cytometry Society: Practical Flow Cytometry in Hematopathology A Case-Based Approach
5000 International Clinical Cytometry Society: Practical Flow Cytometry in Hematopathology A Case-Based Approach Joseph A DiGiuseppe, MD, PhD Hartford Hospital Disclosures In the past 12 months, I have
Prothrombin Time (PT)
Other Names/Abbreviations PT 190.17 - Prothrombin Time (PT) Basic plasma coagulation function is readily assessed with a few simple laboratory tests: the Partial Thromboplastin Time (PTT), Prothrombin
Collecting Cancer Data: Hematopoietic & Lymphoid Neoplasms
Collecting Cancer Data: Hematopoietic & Lymphoid Neoplasms NAACCR 2011 2012 Webinar Series August 2, 2012 1 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If